Notably, loss of Usp18 in KrasLA2/+ mice has been reported to significantly attenuate lung cancer formation, compared to parental KrasLA2/+ mice harboring activated KRAS, pinpointing the implication of USP18 as a potential therapeutic target for cancer treatment. This evidence concerns the gene KRAS and lung carcinoma.